Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25981811 | 1.00 | GAA (0.50) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL999679 | 1.00 | GAA (0.50) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL24818982 | 0.95 | GAA (0.51) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL15192054 | 0.95 | GAA (0.51) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL764580 | 0.95 | GAA (0.51) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL2771992 | 0.88 | GAA (0.54) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL3621203 | 0.88 | GAA (0.54) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL16782174 | 0.83 | GAA (0.46) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL16782405 | 0.83 | GAA (0.46) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL28573430 | 0.80 | GAA (0.50) | GAANFKB1NFKB2RELABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119997954-A | Compounds for the treatment of spinocerebellar ataxia type 3 | PTC医疗公司 | 2025-05-13 | — | — | CN | disclosed |
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
| EP-2651895-B1 | OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS | HOFFMANN LA ROCHE (CH) | 2015-07-01 | — | — | EP | disclosed |
| US-8669254-B2 | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents | HOFFMAN-LA ROCHE INC. (US) | 2014-03-11 | — | — | US | disclosed |
| EP-2651895-A1 | OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20120157476-A1 | OXIME COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| WO-2012080144-A1 | OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718638-B2 | Compounds, compositions and methods for synthesis | ALKBH1, DUT, RNGTT | GAA 624/4885NFKB1 3168/4885NFKB2 3670/4885 |
| US-20120157476-A1 | OXIME COMPOUNDS | APOB, APOL1, PON1 | GAA 919/4885NFKB1 2164/4885NFKB2 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.